Noxopharm Limited (ASX:NOX) has received a green light to proceed with the recruitment of more patients for its anti-cancer drug, NOX66.
It comes as the cancer treatment company received clearance from its Data Safety Monitoring Committee that the drug was non-toxic.
The review of the first group of patients found that after 14 continuous days of NOX66, there were no untoward side-effects.
The trial is on patients with late-stage breast, lung, ovary, prostate and head and neck cancers, who stopped responding to chemotherapy.
The company has now started phase 1b of the combination treatment .
Shares in Noxopharm Limited (ASX:NOX) are trading 2.56 per cent lower to 38 cents.